FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later

Research output: Contribution to journalLetter, comment or opinion

Abstract

The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.
Original languageEnglish
Pages (from-to)1079-1080
Number of pages2
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number5
Early online date14 Feb 2019
DOIs
Publication statusPublished - 1 May 2019

Bibliographical note

This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669.  This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

Fingerprint Dive into the research topics of 'FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later'. Together they form a unique fingerprint.

  • Cite this